NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.08 -0.21 (-3.97 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$5.28
Today's Range$5.08 - $5.30
52-Week Range$4.27 - $9.75
Volume46,325 shs
Average Volume529,469 shs
Market Capitalization$279.13 million
P/E Ratio-12.90
Dividend YieldN/A
Beta1.65
Pieris Pharmaceuticals logoPieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PIRS
CUSIPN/A
Phone857-246-8998

Debt

Debt-to-Equity RatioN/A
Current Ratio3.03
Quick Ratio3.03

Price-To-Earnings

Trailing P/E Ratio-12.90
Forward P/E Ratio-10.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.27 million
Price / Sales10.85
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book19.54

Profitability

EPS (Most Recent Fiscal Year)($0.40)
Net Income$-17,640,000.00
Net Margins-65.40%
Return on Equity-96.56%
Return on Assets-15.25%

Miscellaneous

Employees68
Outstanding Shares53,990,000

Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.15. The biotechnology company earned $4.15 million during the quarter, compared to analyst estimates of $11.39 million. Pieris Pharmaceuticals had a negative return on equity of 96.56% and a negative net margin of 65.40%. View Pieris Pharmaceuticals' Earnings History.

What price target have analysts set for PIRS?

5 brokerages have issued 1 year price objectives for Pieris Pharmaceuticals' shares. Their predictions range from $12.00 to $13.00. On average, they expect Pieris Pharmaceuticals' share price to reach $12.3333 in the next year. View Analyst Ratings for Pieris Pharmaceuticals.

Who are some of Pieris Pharmaceuticals' key competitors?

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen S. Yoder, CEO, Pres & Director (Age 42)
  • Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 43)
  • Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 67)
  • Mr. Claus Schalper MBA, Co-Founder & Sr. Advisor
  • Mr. Ahmed Mousa, VP of Licensing, IP & Legal Affairs and Corp. Compliance Officer

Has Pieris Pharmaceuticals been receiving favorable news coverage?

News articles about PIRS stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.58 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (6.67%), Millennium Management LLC (3.38%), BlackRock Inc. (3.34%), Omega Fund Management LLC (1.45%), Prosight Management LP (1.05%) and Northern Trust Corp (0.66%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

Which institutional investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

Which institutional investors are buying Pieris Pharmaceuticals stock?

PIRS stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, BVF Inc. IL, Prosight Management LP, BlackRock Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Wedge Capital Management L L P NC and EAM Global Investors LLC. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $5.08.

How big of a company is Pieris Pharmaceuticals?

Pieris Pharmaceuticals has a market capitalization of $279.13 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]


MarketBeat Community Rating for Pieris Pharmaceuticals (PIRS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.